Keros Therapeutics Files Routine 8-K for Other Event, Exhibits

TL;DR

**Keros Therapeutics filed a standard 8-K, no major news disclosed.**

AI Summary

Keros Therapeutics, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates a routine disclosure of an event that occurred on January 9, 2024, and does not detail specific financial impacts or major corporate actions. For investors, this filing is primarily administrative, signaling that the company is maintaining its regulatory compliance without revealing new material information that would immediately alter the stock's valuation or outlook.

Why It Matters

This filing is a standard regulatory update, indicating Keros Therapeutics is fulfilling its disclosure obligations. It doesn't contain specific news that would directly impact the stock price, but consistent compliance is a positive sign for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not introduce new risks or significant changes to the company's operations or financial standing.

Analyst Insight

A smart investor would note this as a routine compliance filing and understand that no new material information affecting Keros Therapeutics' valuation has been disclosed. Further research into the 'Other Event' would be needed if more details were provided in an exhibit, but none are specified here.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 9, 2024 (date) — date of earliest event reported and filing date
• 001-39264 (other) — Commission File Number for Keros Therapeutics
• Delaware (other) — state of incorporation for Keros Therapeutics
• Nasdaq Stock Market LLC (company) — exchange where Keros Therapeutics' common stock is registered

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
• $40.00 — on stock, at a public offering price of $40.00 per share (the "Offering") on January 8
• $151.3 million — g offering expenses, were approximately $151.3 million. All of the common stock was offered by
• $68.5 million — 2023 and net proceeds of approximately $68.5 million from the sale of shares of its common s

Filing Documents

• kros-20240109.htm (8-K) — 37KB
• exhibit9911924pr.htm (EX-99.1) — 10KB
• 0001664710-24-000010.txt ( ) — 178KB
• kros-20240109.xsd (EX-101.SCH) — 2KB
• kros-20240109_lab.xml (EX-101.LAB) — 24KB
• kros-20240109_pre.xml (EX-101.PRE) — 13KB
• kros-20240109_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 9, 2024, Keros Therapeutics, Inc. (the "Company") announced the closing of the previously announced underwritten public offering of 4,025,000 shares of common stock, at a public offering price of $40.00 per share (the "Offering") on January 8, 2024, inclusive of the underwriters' exercise in full of their option to purchase up to an additional 525,000 shares of common stock at the public offering price (the "Option"), and issued a press release. The net proceeds to the Company from the Offering, before deducting offering expenses, were approximately $151.3 million. All of the common stock was offered by the Company. Based on its current operating plan, as a result of the full exercise of the Option, the Company believes that the net proceeds from the Offering, together with its cash and cash equivalents as of September 30, 2023 and net proceeds of approximately $68.5 million from the sale of shares of its common stock pursuant to its at-the-market sales agreement subsequent to September 30, 2023, will enable the Company to fund its planned operating expenses and capital expenditure requirements into 2027. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize, including those risk factors discussed or referred to in the Company's filings with the SEC, includ

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 9 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR